McKesson Corporation (VIE:MCK)
Austria · Delayed Price · Currency is EUR | Market Cap | 96.85B +21.2% |
| Revenue (ttm) | 359.73B +8.8% |
| Net Income | 4.02B +45.1% |
| EPS | 32.81 +50.2% |
| Shares Out | n/a |
| PE Ratio | 24.10 |
| Forward PE | 20.06 |
| Dividend | 2.92 (0.36%) |
| Ex-Dividend Date | Sep 1, 2026 |
| Volume | n/a |
| Open | 814.60 |
| Previous Close | 821.20 |
| Day's Range | 812.40 - 822.20 |
| 52-Week Range | 750.20 - 828.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services f... [Read more]
Financial Performance
In fiscal year 2026, McKesson's revenue was $403.43 billion, an increase of 12.36% compared to the previous year's $359.05 billion. Earnings were $4.76 billion, an increase of 44.52%.
Financial numbers in USD Financial StatementsNews
CD&R, McKesson to Acquire At-Home Infusion Therapy Provider for $5.8 Billion
Under the agreement, CD&R will hold a majority interest of about 51% in Option Care Health, while McKesson will hold about 49%.
McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice on Tuesday agreed to take infusion therapy provider Option Care Health private in a deal worth about $5.8 billion including ...
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
NEW YORK & IRVING, Texas & BANNOCKBURN, Ill.--(BUSINESS WIRE)--CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today t...
McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports
Drug distributor McKesson and private equity firm Clayton Dubilier & Rice are nearing a deal to acquire infusion services provider Option Care Health in a transaction valued at more than $5 billion ...
CVS extensions ‘a clearing event’ for McKesson, Cardinal Health, says BofA
BofA reiterates Buy ratings on McKesson (MCK) and Cardinal Health (CAH) after both companies announced deals to extend distribution agreements with CVS Health (CVS). The extension of the CVS contracts...
McKesson enters agreement to extend distribution agreements with CVS Health
McKesson Corporation (MCK) signed an agreement in principle to extend its partnership with CVS Health (CVS) to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies, and...
McKesson reaffirms FY27 adjusted EPS view $44.20-$45.00, consensus $44.65
McKesson (MCK) Corporation is reaffirming its fiscal year 2027 adjusted EPS guidance of $44.20 to $45.00 and its long-term adjusted EPS growth rate of 13% to 16%. Published first on…
McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to...
McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2027 financial results after market close on Wednesday, November 4, 2026. The company will host ...
McKesson Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Double-digit growth was achieved in key segments, with raised EPS and AOI guidance reflecting strong momentum. The PMG acquisition enhances oncology and biopharma capabilities, while capital deployment remains focused on growth and shareholder returns. Continued expansion in specialty platforms and confidence in navigating policy changes were emphasized.
McKesson Transcript: Wells Fargo 21st Annual Healthcare Conference
Strategic focus remains on oncology, biopharma, and supply chain, highlighted by the $2.25B Precision Medicine Group acquisition, robust Q1 growth in key segments, and disciplined capital allocation. AI and technology investments, stable generics, and biosimilar opportunities support a positive outlook.
Hackers claim millions of patient records stolen during data breach at healthcare giant McKesson
A prolific hacking group has taken credit for last week's cyberattack against U.S. pharmaceutical distribution giant McKesson, leading to the latest spill of highly sensitive health data by an America...
McKesson announces cybersecurity incident, investigation in early stages
In a regulatory filing, the company stated, “On August 25, 2026, McKesson (MCK) Corporation discovered a cybersecurity incident affecting its information systems. An investigation of the incident is i...
Morgan Stanley views Precision Medicine as logical addition to McKesson platform
Commenting on McKesson’s (MCK) acquisition of Precision Medicine Group for $2.25B, Morgan Stanley says the company’s CRO acquisition was a long time coming. Precision Medicine Group advances McKesson’...
McKesson signs agreement to acquire Precision Medicine Group
McKesson (MCK) announced that it signed a definitive agreement to acquire Precision Medicine Group, a global provider of clinical research and biopharma commercialization services. McKesson will acqui...
McKesson to buy Precision Medicine Group in about $2.25 billion deal
U.S. drug distributor McKesson said on Tuesday it would buy clinical research and biopharma commercialization services provider Precision Medicine Group in a deal valued at about $2.25 billion.
McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire Precision Medicine Group, LLC (“Precision Medicine Group”), a global p...
McKesson price target raised to $1,000 from $925 at Barclays
Barclays analyst Glen Santangelo raised the firm’s price target on McKesson (MCK) to $1,000 from $925 and keeps an Overweight rating on the shares. The firm updated the company’s model…
McKesson initiated with a Sector Perform at RBC Capital
RBC Capital analyst Ryan Halsted initiated coverage of McKesson (MCK) with a Sector Perform rating and $845 price target The firm believes the company’s integrated model and specialty drug exposure…
McKesson raises annual profit forecast on strong growth in specialty drug business
Drug distributor McKesson on Wednesday raised its annual profit forecast after beating first-quarter earnings estimates, on strength in its oncology and specialty drug businesses.
McKesson Earnings Call Transcript: Q1 2027
Revenue grew 8% to $105.4B and adjusted EPS rose 20% to $9.93, with three segments posting double-digit profit growth. Full-year EPS guidance was raised, supported by strong specialty and GLP-1 demand, robust cash flow, and continued capital returns.
McKesson Earnings release: Q1 2027
McKesson released its Q1 2027 earnings on August 5, 2026, summarizing the period's financial results.
McKesson Slides: Q1 2027
McKesson has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 5, 2026.
McKesson Quarterly report: Q1 2027
McKesson has published its Q1 2027 quarterly earnings report on August 5, 2026.